IL6 and COVID-19: Consequently, COVID-19 patients developing ARDS have increased plasma levels of pro-inflammatory cytokines, such as interleukins-1 beta and -6 (IL-1β, IL-6), tumor necrosis factor alpha (TNF-α), chemokines—CXCL10 (IP-10), CCL2 (monocyte chemoattractant protein-1, MCP-1), and CCL3 (macrophage inflammatory protein-1 alpha, MIP-1α) (9, 10).